Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market

CHASKA, Minn. and TORRANCE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract development and manufacturing, today announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical customers in the U.S.

The collaboration will leverage PolyPeptide’s strong capabilities in peptide manufacturing and development in combination with Lifecore’s expertise in formulation, fill/finish, and packaging. The companies intend to work together to offer a seamless transition between drug substance (DS) and drug product (DP), which is designed to enable customers to accelerate development timelines, reduce development costs and risks, and enjoy the reliability and regulatory alignment that comes with a fully U.S.-based supply chain.

“This collaboration brings together two leading organizations, each an expert in its field, to deliver value to peptide-based pharmaceutical developers. Together, we expect to optimize product development activities through a range of collaborative studies and assessments, and by streamlining the supply chain, aim to help customers meet their development milestones,” said Mark DaFonseca, chief commercial officer, Lifecore Biomedical.

“By aligning our technical and commercial strengths, we believe we are uniquely positioned to help customers navigate complex development challenges and bring innovative therapies to market faster. Together, the companies anticipate jointly supporting laboratory transfers, equipment comparability, method transfer and release testing, thus ensuring robust technical oversight and quality through the entire process,” added Trishul Shah, global director of business development and head of sales, PolyPeptide.

About PolyPeptide Group
PolyPeptide Laboratories, Inc., based in Torrance, CA, is a subsidiary of PolyPeptide Group AG (SIX: PPGN). PolyPeptide is a specialized CDMO for peptide-based active pharmaceutical ingredients. PolyPeptide serves a fast growing market, and is a global leader in peptide development and manufacturing, offering comprehensive solutions from early-stage development to commercial supply. www.polypeptide.com.

About Lifecore Biomedical

Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as “anticipate”, “estimate”, “expect”, “project”, “aim”, “designed to”, “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements. In addition, all statements regarding our collaboration agreement with PolyPeptide and the expected benefits to us, PolyPeptide and customers are forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors among others, the timing and amount of future expenses, revenue, Adjusted EBITDA, cash flow and capital requirements, and timing and availability of and the need for additional financing; our ability to maintain or expand our relationships with our current customers, including the impact of changes in consumer demand for the products we manufacture for our customers; our ability to grow and diversify our business with new customers, including the potential loss of development customers if they do not receive required funding or regulatory approvals, or for other reasons; our ability to comply with covenants under our credit agreements and to pay required interest and principal payments when due; our ability to raise additional capital for ongoing needs, including through equity financing, debt financing, collaborations, strategic alliances or licensing arrangements; the impact of macroeconomic events or circumstances on our operations and financial performance, including inflation, tariffs, interest rates, social unrest and global instability; the performance of our third-party suppliers; pharmaceutical industry market forces that may impact our customers’ success and continued demand for the products we produce for those customers; our ability to recruit or retain key scientific, technical, business development, and management personnel and our executive officers; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including current Good Manufacturing Practice, or cGMP; the outcome and cost of existing and any new litigation or regulatory proceedings; and other risk factors set forth from time to time in the company’s SEC filings, including, but not limited to, the Annual Report on Form 10-K for the year ended May 25, 2025 (the “2025 10-K”). For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the Securities and Exchange Commission, including the risk factors contained in the 2025 10-K. Forward-looking statements represent management’s current expectations as of the date hereof and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.

CONTACT: Lifecore Biomedical, Inc. Contact Information:

Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
sdiaz@vidasp.com

Tim Brons (Media)
415-675-7402
tbrons@vidasp.com

Ryan D. Lake (CFO)
Lifecore Biomedical
952-368-6244
ryan.lake@lifecore.com

PolyPeptide Contact Information:

Trishul Shah (Global Director Business Development and Head of Sales)
Trishul.Shah@polypeptide.com

Lauren Starr (Senior Manager Corporate Communications)
Lauren.Starr@polypeptide.com